Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study

PURPOSE: Biliary cancers overexpress epidermal growth factor receptor (EGFR), and angiogenesis has been correlated with poor outcome. Erlotinib, an EGFR tyrosine kinase inhibitor, and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor have each been shown to have activity in biliary...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lubner, Sam J., Mahoney, Michelle R., Kolesar, Jill L., LoConte, Noelle K., Kim, George P., Pitot, Henry C., Philip, Philip A., Picus, Joel, Yong, Wei-Peng, Horvath, Lisa, Van Hazel, Guy, Erlichman, Charles E., Holen, Kyle D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917213/
https://ncbi.nlm.nih.gov/pubmed/20530271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.28.4075
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados